EBITDA: Income before interest, taxes, depreciation and amortization.
Satellos Bioscience Inc. (MSLE) had EBITDA of $-11.66M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-11.17M |
|
-- |
|
-- |
|
$11.66M |
|
$-11.66M |
|
$0.54M |
|
$-11.13M |
|
$-11.13M |
|
$-11.17M |
|
$-11.17M |
|
$-11.17M |
|
$-11.09M |
|
$-11.66M |
|
|
EBITDA |
$-11.66M |
21.18M |
|
21.18M |
|
$-0.53 |
|
$-0.53 |
|
| Balance Sheet Financials | |
$57.98M |
|
$0.01M |
|
$0.01M |
|
$57.98M |
|
$8.36M |
|
-- |
|
-- |
|
$8.36M |
|
$49.62M |
|
$49.62M |
|
$49.62M |
|
21.22M |
|
| Cash Flow Statement Financials | |
$-25.85M |
|
$-29.03M |
|
$51.32M |
|
$9.80M |
|
$6.17M |
|
$-3.63M |
|
$2.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-25.85M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-22.51% |
|
-22.51% |
|
-19.26% |
|
-22.51% |
|
$2.34 |
|
$-1.22 |
|
$-1.22 |
|